{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"OSDI is a patient reported questionnaire consisting of 12 questions which are scored from 0 to 4. The total scored is computed and depending on the number of questions answered scores are computed which are then categorized into mild, moderate or severe dry eye symptoms. This tool should adequately reflect the morbidity of the dry eye symptoms.","groups":[{"description":"Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.\n\ncyclosporine ophthalmic emulsion: Given as eye drops","id":"OG000","title":"Arm I"},{"description":"Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.\n\nplacebo: Given as eye drops","id":"OG001","title":"Arm II"}],"populationDescription":"Not collected/analysed due to staffing constraints","reportingStatus":"POSTED","timeFrame":"1 year after transplant","title":"Numerical Score of Ocular Surface Disease Index (OSDI) and Development or Lack of Ocular GVHD (by Ophthalmologic Examination) as Measured by Odds Ratio in a Linear Regression Model.","type":"SECONDARY"}